Skip to main content
. Author manuscript; available in PMC: 2017 Jun 8.
Published in final edited form as: Leukemia. 2016 Nov 14;31(6):1415–1422. doi: 10.1038/leu.2016.326

Figure 6. Rapamycin abrogates cytokine-induced overgrowth of JMML patient cells with the PTPN11E76K mutation.

Figure 6

(A) BM cells (1×104 cells/mL) from five JMML patients with the indicated PTPN11 mutations and three normal donors were plated in methylcellulose medium containing GM-CSF (1.0 ng/mL) and Rapamycin at the indicated concentrations. Colonies were enumerated 14 days later and normalized against the number of the colonies derived without Rapamycin treatment. (B) BM cells from five JMML patients with the indicated PTPN11 mutations and normal donors were cultured in IMDM containing GM-CSF (1.0 ng/mL) and Rapamycin (2.5 nM) or vehicle. Cell numbers were determined using the One Solution Cell Proliferation Assay kit. Data shown are mean±S.D. of all samples tested.